FOXO · Foxo Technologies Inc.
Substantial doubt about the company's ability to continue as a going concern.
“Until additional equity or debt capital is secured, there is substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed Aug 14, 2026
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | -$519,750 | Three Months Ended June 30, 2026 filing | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
FOXO
this stock
Foxo Technologies Inc.
|
$116,068 | — | +304.0% | — | 0.0% |
|
HCA
HCA Healthcare, Inc.
|
$103.32B | -1.6% | +7.1% | 15.6 | 2.2% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$28.30B | -12.4% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$21.93B | +35.4% | +0.9% | 10.5 | 2.3% |
|
EHC
Encompass Health Corp
|
$12.00B | +13.5% | +10.5% | 19.8 | 3.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- % held
- 0.0%
- Net QoQ
- +181 sh
- Top holder
- Garton & Associates Finan…
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| FOXO | -94.1% | -97.2% | -99.8% | -95.4% | -99.9% |
| SPY | +1.9% | +3.3% | +5.7% | +2.0% | +10.0% |
| vs SPY | -96.0% | -100.5% | -105.5% | -97.4% | -109.9% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.